Dr. Csaba P. Kovesdy, M.D.
Nephrology (Kidney) (Nephrology Physician)
At a glance
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
VA license 0101230409
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 15 payments worth $10,912 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $9,612 |
|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,300 |
| Consulting Fee | $9,175 |
|---|---|
| Travel and Lodging | $1,327 |
| Food and Beverage | $410 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Aug 16, 2025 | Consulting Fee Kerendia · Cardio-Renal | $7,875 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 3, 2025 | Consulting Fee JARDIANCE · DIABETES | $1,300 |
| Bayer HealthCare Pharmaceuticals Inc. Aug 16, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind | $408 |
| Bayer HealthCare Pharmaceuticals Inc. Aug 16, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind | $285 |
| Bayer HealthCare Pharmaceuticals Inc. Aug 15, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind | $215 |
| Bayer HealthCare Pharmaceuticals Inc. Aug 15, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind | $198 |
| Bayer HealthCare Pharmaceuticals Inc. Aug 16, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind | $130 |
| Bayer HealthCare Pharmaceuticals Inc. Aug 16, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind | $59.70 |
| Bayer HealthCare Pharmaceuticals Inc. Aug 17, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Chicago, IL · in-kind | $30.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $36,281 in research payments for these studies, mostly to the institutions running them.
- A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease
Boehringer Ingelheim International GmbH - A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
AstraZeneca Pharmaceuticals LP - A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension
Novartis Pharmaceuticals Corporation - BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chron…
Bayer HealthCare Pharmaceuticals Inc. - BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic
Bayer HealthCare Pharmaceuticals Inc. - A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with R…
AstraZeneca Pharmaceuticals LP - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.